Log In
BCIQ
Print this Print this
 

OHR3031

  Manage Alerts
Collapse Summary General Information
Company Ohr Pharmaceutical Inc.
DescriptionSmall molecule anti-angiogenic compound
Molecular Target
Mechanism of ActionAngiogenesis inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationChoroidal neovascularization (CNV)
Indication DetailsTreat choroidal neovascularization (CNV)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today